Antibe Therapeutics Inc. (OTCMKTS:ATBPF) Short Interest Update

Antibe Therapeutics Inc. (OTCMKTS:ATBPF) was the recipient of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 8,900 shares, a decline of 73.1% from the February 29th total of 33,100 shares. Based on an average daily volume of 88,700 shares, the short-interest ratio is currently 0.1 days.

Analyst Ratings Changes

Separately, Brookline Capital Management cut shares of Antibe Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, March 4th.

Antibe Therapeutics Trading Down 1.6 %

Shares of OTCMKTS ATBPF opened at $0.32 on Thursday. The firm has a market cap of $16.85 million, a P/E ratio of -1.27 and a beta of 0.57. The business’s 50 day moving average is $0.58 and its 200-day moving average is $0.55. Antibe Therapeutics has a 1-year low of $0.24 and a 1-year high of $0.89.

Antibe Therapeutics (OTCMKTS:ATBPF) last issued its quarterly earnings data on Wednesday, February 14th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.03. Analysts forecast that Antibe Therapeutics will post -0.3 EPS for the current year.

Antibe Therapeutics Company Profile

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).